See every side of every news story

Published 12 days ago • loading... • Updated 12 days ago

Libtayo Approved in Scotland for Recurrent Cervical Cancer Treatment

Summary by healtheconomics.com

The Scottish Medicines Consortium (SMC) has approved Libtayo (cemiplimab) for use in the National Health Service, making it the first immunotherapy available for adults with recurrent or metastatic cervical cancer in the country. This approval is significant for patients whose cancer has progressed after platinum-based chemotherapy, as advanced cervical cancer has very limited treatment options and low survival rates. In Scotland, only 20% of wo…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

healtheconomics.com

Libtayo Approved in Scotland for Recurrent Cervical Cancer Treatment

The Scottish Medicines Consortium (SMC) has approved Libtayo (cemiplimab) for use in the National Health Service, making it the first immunotherapy available for adults with recurrent or metastatic cervical cancer in the country. This approval is significant for patients whose cancer has progressed after platinum-based chemotherapy, as advanced cervical cancer has very limited treatment options and low survival rates. In Scotland, only 20% of wo…

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated11 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

healtheconomics.com broke the news in 12 days ago on Tuesday, February 11, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics